Intellia Therapeutics Inc Stock
Intellia Therapeutics Inc gained 0.110% compared to yesterday.
Our community is currently high on Intellia Therapeutics Inc with 26 Buy predictions and 5 Sell predictions.
Based on the current price of 9.36 € the target price of 24 € shows a potential of 156.41% for Intellia Therapeutics Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Intellia Therapeutics Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 0.110% | -0.426% | -39.457% | -5.721% | 19.908% | -73.811% | -92.000% |
| Chromadex Corp | -0.680% | 2.113% | -2.027% | -62.092% | -47.273% | 94.631% | -60.274% |
| Cardio3 Biosciences S.A. | -4.330% | -11.245% | 13.333% | -38.440% | 63.704% | -50.889% | -93.500% |
| Polynovo Ltd | 0.000% | 5.172% | -12.072% | -25.496% | -28.235% | -44.545% | -65.390% |
Comments
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $49.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its price target lowered by HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
News
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
An exciting new CRISPR-based tool is making waves in the scientific literature this spring. Because the new technology destroys targeted diseased cells outright rather than editing their genetic
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
Intellia Therapeutics (NASDAQ: NTLA) has been on fire this year. Shares of the clinical-stage biotech have climbed an impressive 83% to date. However, Wall Street remains bullish on the company
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Choosing between Intellia Therapeutics (NASDAQ:NTLA) and Omeros (NASDAQ:OMER) in 2026 requires balancing the explosive potential of gene editing against the steady rollout of newly approved orphan